JaxBio, an Israeli diagnostics firm, is expanding access to DNA methylation-based liquid biopsy testing using a hybridization microarray-based platform. The company’s focus starts with lung cancer and includes moving toward broader clinical adoption for early detection and therapeutic monitoring. In colorectal screening, updated data for Freenome’s blood-based test improved on earlier performance, reinforcing the competitive pressure for noninvasive colorectal cancer diagnostics. Evercore ISI analysts tied the development to Abbott’s existing go-to-market agreement with Freenome, highlighting how incremental improvements in analytical sensitivity and specificity can reshape screening uptake.